Metal oxidation sunscreen formulations

A metal oxide sunscreen formulation with zinc oxide, squalane, and antioxidants addresses the limitations of traditional metal oxide and chemical sunscreens by offering high SPF and broad spectrum protection without residue, enhancing UV blocking efficacy.

CN119074571APending Publication Date: 2024-12-06AMYRIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411119351.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-01-30
Filing Date
2021-01-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing metal oxide sunscreens leave a white residue and do not provide broad spectrum protection, while chemical sunscreens pose health risks, necessitating the development of metal oxide formulations that are non-powdery, residue-free, and offer high sun protection factor (SPF) with broad spectrum action.

Method used

A metal oxide sunscreen formulation containing zinc oxide or titanium oxide, squalane, antioxidants like ethyl ferulate, and additional ingredients such as solvents, chelating agents, surfactants, emulsion stabilizers, thickeners, emulsifiers, and preservatives, which enhance UV blocking ability and reduce residue.

Benefits of technology

The formulation provides high SPF, broad spectrum protection, and avoids the drawbacks of traditional metal oxide and chemical sunscreens by being non-powdery and residue-free, effectively blocking UVA and UVB rays.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074571A_ABST
    Figure CN119074571A_ABST
Patent Text Reader

Abstract

The invention relates to metal oxidation sunscreen formulations. The present invention provides a sunscreen formulation containing a metal oxide sunscreen, squalane, and an antioxidant. The provided sunscreen formulation has a higher SPF per unit mass of metal oxide compared to a sunscreen formulation containing a metal oxide but not adding squalane and an antioxidant. The present invention also provides a method of preventing UV damage to the skin involving the application of the sunscreen formulation.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with an application date of January 29, 2021, application number "202180011409.1", and invention name "Metal Oxide Sunscreen Preparation". The original application is the Chinese national phase application of the international application PCT / US2021 / 015666. Technical Field

[0002] The present application relates to metal oxide sunscreen formulations. Background Art

[0003] It is well known that overexposure to sunlight causes many health problems, including increased incidence of various skin cancers and accelerated skin aging. Radiation in the ultraviolet (UV) range (200nm to 400nm) is associated with most of the harmful effects of sunlight exposure. In order to mitigate the harmful effects of sunlight, many products have been developed to block or attenuate UV energy. These products block UV radiation and their relative effectiveness is measured using a measure called the Sun Protection Factor (SPF). Two different types of UV filters have been developed: metal oxide sunscreens and chemical sunscreens. Metal oxides are very useful sunscreens, but they are characterized by a dry or powdery application that often leaves a white residue. In contrast, chemical sunscreens apply more effectively and are usually absorbed without a visible residue. However, recent studies have shown that chemical sunscreens may have concerning health effects.

[0004] UV rays are divided into three different categories based on their energy. The highest energy radiation is called UVC (200nm to 290nm). Fortunately, however, UVC is absorbed by the atmosphere and does not pose a significant exposure risk. The second category of UV rays is UVB (290nm to 320nm), which is responsible for most of the acute effects of UV exposure, such as immunosuppression, the appearance of erythema, and the induction of skin cancer. The third category of UV rays is UVA (320nm to 400nm), which is the least energetic ray. However, UVA penetrates the dermis the deepest of the three.

[0005] In the past, UVA was not considered to damage the skin. In line with this belief, the SPF metric focused on the effects of UVB radiation, which was characterized by measuring the ability of a product to block the formation of erythema. However, it is now widely recognized that UVA is a factor in skin photoaging and can cause certain types of tumors. Therefore, products with high SPF but low UVA protection may put users at risk because they encourage longer sun exposure without effectively blocking UVA rays. Today, products with broader spectrum protection are favored. Such broad spectrum sunscreen products are usually mixtures of two or more UV filter compounds. However, the development of broad spectrum sunscreen products has also caused other problems, because they often contain mixtures of chemical sunscreens that are believed to pose health risks due to their use. Therefore, there is a need for additional broad spectrum sunscreen formulations based on metal oxides that do not have the negative disadvantages of traditional metal oxide sunscreens and the harmful health effects of chemical sunscreens. Summary of the invention

[0006] In one aspect, the present disclosure relates to a metal oxide sunscreen formulation that is non-powdery, does not leave a white residue, and has broad spectrum action and a high sun protection factor (SPF).

[0007] In one embodiment, the sunscreen contains a metal oxide, squalane and one or more antioxidants. In another embodiment, the sunscreen formulation has a higher SPF per unit mass than the metal oxide alone. In yet another embodiment, the metal oxide is selected from zinc oxide and titanium oxide. In a further embodiment, the antioxidant is ethyl ferulate. In another embodiment, the sunscreen formulation contains a solvent. In a preferred embodiment, the solvent is water. In another embodiment, the sunscreen formulation contains a chelating agent. In a preferred embodiment, the chelating agent is selected from sodium gluconate, sodium phytate, EDTA, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate. In yet another embodiment, the sunscreen formulation contains a surfactant. In a preferred embodiment, the surfactant is selected from decyl / octyl glucoside, cocoyl glucoside, isostearic acid, cetearyl glucoside and arachidyl glucoside. In yet another embodiment, the sunscreen formulation contains a humectant. In a preferred embodiment, the humectant is selected from glycerol, 1,2-propylene glycol, 1,3-propylene glycol, hexylene glycol, butylene glycol, sorbitol and xylitol. In a further embodiment, the sunscreen formulation contains an emulsion stabilizer. In a preferred embodiment, the emulsion stabilizer is selected from gum arabic, xanthan gum, cellulose gum, microcrystalline cellulose. In another embodiment, the sunscreen formulation contains a thickener. In a preferred embodiment, the thickener is selected from cetyl palmitate, cetearyl alcohol, methyl dihydroabietic acid, behenyl alcohol, brassicerol, arachidyl alcohol, coconut oil alcohol, sorbitan palmitate. In another embodiment, the sunscreen formulation contains an emulsifier. In a preferred embodiment, the emulsifier is selected from sorbitan olivate, polyglyceryl-3 polyricinoleate, lecithin, glyceryl stearate, cetearyl olivate. In another embodiment, the sunscreen formulation contains other emollients in addition to squalane. In a preferred embodiment, the other emollients in addition to squalane are selected from tricaprylin and tricaprin. In yet another embodiment, the sunscreen formulation contains a dispersant. In a preferred embodiment, the dispersant is selected from polyhydroxystearic acid. In one embodiment, the sunscreen formulation contains a skin conditioner. In a preferred embodiment, the skin conditioning agent is selected from sodium palmitoyl proline and white water lily extract. In another embodiment, the sunscreen formulation contains a preservative. In a preferred embodiment, the preservative is selected from phenoxyethanol, benzyl alcohol, hydroxyacetophenone, chlorphenesin, potassium sorbate. In another embodiment, the sunscreen formulation contains a conditioning agent. In a preferred embodiment, the conditioning agent is ethylhexylglycerin.

[0008] In certain embodiments, the metal oxide comprises about 5% w / w to 25% w / w of the formulation. In other embodiments, squalane comprises about 1% w / w to 25% w / w of the formulation. In other embodiments, the antioxidant comprises about 0.1% w / w to 2% w / w of the formulation. In an embodiment of the present invention, the metal oxide comprises about 14% w / w of the formulation, squalane comprises about 5% w / w, and the antioxidant comprises about 0.7% w / w.

[0009] In another aspect, the present invention provides a method for preventing ultraviolet rays from damaging the skin of a subject, comprising applying an effective amount of the sunscreen formulation disclosed in the present invention to the skin of the subject. In one embodiment of the method, the sunscreen formulation is applied to the skin before exposure to ultraviolet rays. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 It is a graph showing the average absorption spectrum obtained for a blank (control) plate.

[0011] Figure 2 is a graph showing the average absorption spectrum of the UV band when the test panels were coated with the sunscreen research samples before UV exposure.

[0012] Figure 3 is a graph showing the average absorption spectrum in the UV band of the test panel when coated after UV exposure.

[0013] Figure 4 is a graph showing the average absorbance spectra of blank (control) test plates in the broad spectrum protection assay.

[0014] Figure 5 is a graph showing the protection provided by the sunscreen study samples in the broad spectrum protection analysis and critical wavelength calculation. DETAILED DESCRIPTION

[0015] The sunscreen formulations disclosed herein rely on metal oxides (also known as mineral oxide UV agents) as active agents in the formulations. Suitable metal oxides include zinc oxide and titanium oxide. Zinc oxide is the preferred metal oxide for the formulations.

[0016] In addition to the metal oxide sunscreen, the disclosed metal oxide based sunscreen formulations also include one or more antioxidants and squalane. It has been found that the antioxidant combined with squalane increases the SPF of the formulation compared to formulations lacking the antioxidant and squalane. In addition, it has been found that the antioxidant and squalane components enhance the UV blocking ability of the metal oxide. Antioxidants are compounds that inhibit oxidation. A preferred antioxidant is ethyl ferulate.

[0017] As used herein, "squalane" refers to a compound having the following chemical formula:

[0018] The sunscreen formulations of the present invention include squalane. Squalane acts as an emollient in the formulation and can mitigate the unpleasant properties of metal oxide sunscreen compounds, including: reducing the heavy or sticky feel, and reducing or eliminating the powdery surface when applied. Surprisingly, it was also found that the combination of squalane and an antioxidant increased the SPF of the metal oxide sunscreen relative to the amount of metal oxide in the sunscreen. In certain embodiments, squalane comprises about 1% w / w to 25% w / w of the formulation. In another embodiment, squalane comprises about 5% w / w to 20% w / w of the formulation. In a preferred embodiment, the sunscreen formulation comprises about 5% w / w of the formulation.

[0019] The sunscreen formulations disclosed herein may also contain one or more solvents. The solvent is used to dissolve various solutes in the formulation that have one or more functions. The solutes dissolved by the solvent may function as chelating agents, surfactants, wetting agents, emulsion stabilizers, thickeners, emulsifiers, additional emollients other than squalane, dispersants, skin conditioners, preservatives, and conditioning agents. The preferred solvent of the present invention is water.

[0020] The formulation disclosed in the present invention may contain one or more chelating agents. Chelating agents are compounds that react with metal ions to form stable water-soluble complexes. Typical chelating agents include sodium gluconate, sodium phytate, EDTA, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate. The preferred chelating agent of the present invention is sodium gluconate.

[0021] The formulation disclosed in the present invention may contain one or more surfactants. The surfactant serves to reduce the surface tension of one or more liquids in the formulation. Typical surfactants include decyl / octyl glucoside, cocoyl glucoside, isostearic acid, cetearyl glucoside and arachidyl glucoside. Practical surfactants in the formulation include decyl / octyl glucoside, cocoyl glucoside and isostearic acid.

[0022] The formulation disclosed in the present invention may also contain one or more wetting agents. Wetting agents are compounds that retain moisture in the formulation, typically hygroscopic compounds having multiple hydrophilic groups. Wetting agents disclosed herein include glycerol, 1,2-propylene glycol, 1,3-propylene glycol, hexylene glycol, butylene glycol, sorbitol, and xylitol. The preferred wetting agent in the formulation is glycerol.

[0023] The preparation disclosed by the present invention may also contain one or more emulsion stabilizers. Emulsion stabilizers are used to keep the droplets constituting the emulsion from agglomerating. Typical emulsion stabilizers include gum arabic, xanthan gum, cellulose gum, microcrystalline cellulose. Preferred emulsion stabilizers of the preparation include gum arabic and xanthan gum.

[0024] The formulation disclosed in the present invention may include one or more thickeners. Thickeners are compounds that thicken the formulation and thereby increase the overall viscosity of the sunscreen formulation. Typical thickeners include cetyl palmitate, cetearyl alcohol, methyl dihydroabietate, behenyl alcohol, brassic alcohol, arachidyl alcohol, coconut oil alcohol, sorbitan palmitate. Preferred thickeners include cetyl palmitate, cetearyl alcohol and methyl dihydroabietate.

[0025] The formulation disclosed in the present invention may include one or more emulsifiers. Emulsifiers are compounds that keep different chemical substances (such as hydrophobic and hydrophilic compounds) from separating in an emulsion. Typical emulsifiers include sorbitan olivate, polyglyceryl-3 polyricinoleate, lecithin, stearyl glyceryl, cetearyl olivate. Preferred emulsifiers include sorbitan olivate, polyglyceryl-3 polyricinoleate and lecithin.

[0026] The formulation disclosed herein may include one or more emollients in addition to squalane. Emollients are substances that soften the skin by slowing down or preventing the evaporation of water. Squalane functions as an emollient. However, one or more other emollients may be added to the formulation. Suitable emollients in addition to squalane include tricaprylin and tricaprin.

[0027] The formulations disclosed herein may contain one or more dispersants. Dispersants are compounds that improve the separation of particles in suspension or colloidal dispersions and reduce the sedimentation or aggregation of specific compounds in the formulation. A preferred dispersant for the formulation is polyhydroxystearic acid.

[0028] The formulations disclosed herein may contain one or more skin conditioning agents. Suitable skin conditioning agents include sodium palmitoyl proline, white water lily extract, and ethylhexylglycerin.

[0029] The preparation disclosed in the present invention may contain one or more preservatives. Typical preservatives include phenoxyethanol, benzyl alcohol, hydroxyacetophenone, chlorphenesin, potassium sorbate. A preferred preservative is phenoxyethanol.

[0030] As used herein, "effective amount" refers to the amount necessary to at least partially achieve the desired relief effect for the specific symptoms being treated, or to delay the onset or inhibit the progression, or to completely stop the onset or progression. The amount varies depending on the health and physical condition of the subject being treated, the classification group of the subject being treated, the degree of protection required, the formulation of the composition, the assessment of the medical condition, and other relevant factors. It is expected that the amount will fall within a relatively large range that can be determined by routine experiments.

[0031] As used herein, a "subject" or "patient" is an organism that is treated using the methods of the present disclosure. In one embodiment, the subject is a mammalian subject, such as a human or livestock.

[0032] As used herein, the term "about" will be understood by those of ordinary skill in the art and will vary to some extent depending on the context of use. If the use of the term is not clear to one of ordinary skill in the art in the context of use, "about" may refer to a range of plus or minus 20% of the specific term.

[0033] As used in the present invention, the term "ointment" may be any generally known commercially available ointment.

[0034] As used herein, "UV" and "ultraviolet radiation" refer to light having a wavelength of 200 nm to 400 nm.

[0035] As used herein, "UVA" and "ultraviolet long wave radiation" refer to light having a wavelength of 320 nm to 400 nm.

[0036] As used herein, "UVB" and "ultraviolet radiation" refer to light having a wavelength of 290 nm to 320 nm.

[0037] As used herein, "UVC" and "short-wave ultraviolet radiation" refer to light having a wavelength of 200 nm to 290 nm.

[0038] Example

[0039] Example 1: In vitro UVA sun protection index and critical wavelength determination

[0040] Research Design and Methods

[0041] Sunscreen study samples containing metal oxide sunscreens, squalane and antioxidants were prepared (see Table 1). Measurement of the sun protection factor (SPF) of sunscreens was performed using an in vitro assay. The in vitro assay was based on PMMA (polymethyl methacrylate) plates with a 6 micron roughened surface (Helioplates HD6 supplied by Helioscreen).

[0042] Table 1: Ingredients of sunscreen preparations

[0043]

[0044]

[0045] The sunscreen research samples were concentrated at about 1.3 mg / cm 2 The amount of coating is applied on four PMMA plates with a size of about 25cm 2The sunscreen study samples were manually spread on the PMMA plate surface using fingertips that had been previously dipped in the sunscreen formulation. The samples were placed in a light-proof drying oven maintained at 29.1 to 29.2°C and dried for 30 minutes.

[0046] The control panels were treated similarly, except that a glycerin control was applied instead of the sunscreen study samples. The absorbance spectra of the control panels were measured in the range of 290 nm to 400 nm at 1 nm intervals. Five spectra were taken from five different locations on each panel. The reading area for each location was 0.79 cm 2 .

[0047] The absorption spectra of the sunscreen study samples were measured in the range of 290nm to 400nm using the control plate as a reference value at 1nm intervals. Five spectra of the sunscreen study samples were obtained at five different locations on the plate. The initial in vitro SPF (SPF) was calculated using the average absorption spectrum of each plate using the following formula 体外 ):

[0048]

[0049] in:

[0050] E λ : Erythema effect spectrum;

[0051] I λ : UV range simulated spectrum irradiation;

[0052] A 0λ : Average monochromatic light absorbance of sunscreen preparations before UV exposure;

[0053] d λ : Wavelength increment.

[0054] Next, determine the adjustment factor C used to make the calculated results and the in vitro SPF values ​​equal to the values ​​obtained in the in vivo test. Iterate the calculation of C values ​​to meet the condition:

[0055]

[0056] in:

[0057] E λ : Erythema effect spectrum;

[0058] I λ : UV range simulated spectrum irradiation;

[0059] A 0λ : Average monochromatic light absorbance of sunscreen preparations before UV exposure;

[0060] C: the adjustment factor determined previously in the formula;

[0061] d λ : Wavelength increment.

[0062] According to the reference standard, the value of coefficient C must be within the range of 0.8 to 1.6. If a value outside the determined range is obtained, a new test panel should be prepared to verify the obtained result.

[0063] Using these data, the initial UVA-PF (UVA-PF0) of the product was calculated by the following formula:

[0064]

[0065] in:

[0066] P λ : Persistent pigmentation effect spectrum;

[0067] I λ : UV range simulated spectrum irradiation;

[0068] A 0λ : Average monochromatic light absorbance of sunscreen preparations before UV exposure;

[0069] C: the adjustment factor determined previously in the formula;

[0070] d λ : Wavelength increment.

[0071] All four PMMA plates containing the sunscreen study samples were exposed to controlled doses of UV radiation to place the sunscreen study samples under conditions close to reality. An irradiation box UV Atlas (model Suntest CPS+) equipped with UV special glass filters was used. The sunscreen study samples were exposed to radiation in the UVA, UVB and visible light ranges, with doses in a manner that provided a quantitative amount of energy D (J / cm 2 ) is calculated as follows:

[0072] D=UVA-PF0×D0

[0073] Where D0 is defined by ISO 24443 as 1.2 J / cm 2 of UVA radiation dose.

[0074] The temperature of the UV exposure chamber was monitored throughout the process and maintained between 28.9°C and 33.6°C.

[0075] After the sunscreen study samples were exposed to UV radiation, the absorbance of each of the four test panels was measured again according to the above procedure, and five spectra were finally obtained for each test panel. Using the average absorption spectrum of each test panel, the UVA-PF was determined according to the following formula:

[0076]

[0077] in

[0078] P λ : Persistent pigmentation effect spectrum;

[0079] I λ : UV range simulated spectrum irradiation;

[0080] A 0λ : Average monochromatic light absorbance of sunscreen preparations after UV exposure;

[0081] C: the adjustment factor determined previously in the formula;

[0082] d λ : Wavelength increment.

[0083] The SPF / UVA-PF ratio was also calculated from the in vivo SPF values.

[0084] The critical wavelength (λc) is calculated based on the absorbance spectra after UV exposure for the sunscreen study samples applied to all test panels. The critical wavelength is another measure of the UVA protection of the sunscreen formulation and is defined as the lower wavelength at which the absorbance of the sunscreen study sample is equal to 90% of the total absorbance according to the following formula:

[0085]

[0086] in

[0087] λc: critical wavelength;

[0088] A λ : Average monochromatic light absorbance of the product after UV exposure.

[0089] Reference material S2 is tested according to the same procedure as above. The average UVA-PF value of the reference material after irradiation must be in the range of 10.7 to 14.7.

[0090] result

[0091] The determination of the UVA-PF of the sunscreen study sample was repeated in four test panels. The UVA-PF of the sample was calculated by averaging the UVA-PF obtained for each test panel. The SPF / UVA-PF ratio and λc of the sunscreen study sample were calculated in the same manner. Then, the 95% confidence interval (CI95%) of the UVA-PF of the sunscreen study sample and the reference material was determined using the following formula:

[0092]

[0093] in,

[0094]

[0095] in:

[0096] Average UVA-PF;

[0097] s: standard deviation of the mean;

[0098] CI95%: lower and upper limits of the 95% confidence interval;

[0099] n: number of test boards;

[0100] t: two-sided Student’s t distribution value with n-1 degrees of freedom and 95% confidence level.

[0101] The ratio between c and UVA-PF corresponds to CI [%], which is calculated according to the following formula:

[0102]

[0103] For the product and reference material S2, the test results are considered valid if the mean UVA-PF of reference S2 is within the expected range and the c-value is not higher than 17% of the mean UVA-PF (CI [%] < 17.0).

[0104] Figure 1 Shown is the average absorption spectrum obtained for the control test plate, while Figure 2 Shown is the average absorption spectrum obtained for all test panels coated with the sunscreen study samples. Table 2 shows the respective values ​​of in vitro SPF, adjustment factor C and UVA-PF0 calculated for the test panels individually. The adjustment factor C was calculated to adjust the in vitro SPF to an in vivo value of 30.

[0105] Table 2: Data on the amount of sunscreen study samples applied and the UVA sun protection factor and irradiated UVA dose before UVA exposure.

[0106]

[0107] *C: adjustment factor determined previously in the formula;

[0108] The samples were exposed to UV light in an irradiation box that was calibrated every 18 months. The spectral irradiance of the sunlight simulation box in the range of 320nm to 400nm (UVA) was 78.78W / m 2 . Figure 3 Shown are the average absorbance spectra of the test panels treated with the sunscreen study samples after UV exposure. Table 3 shows the individual UVA-PF values ​​calculated for each test panel individually and Table 4 shows the average UVA-PF and 95% confidence intervals for the sunscreen formulations.

[0109] Table 3: Final UVA-PF values, ratio between SPF / UVA-PF and critical wavelength (λc) of sunscreen formulations.

[0110] Plate No. In vitro UVA-PF SPF / UVA-PF λc(nm) 1 15.1 2.0 375 2 16.0 1.9 375 3 15.7 1.9 375 4 15.8 1.9 375 average 15.6 1.9 375 Standard Deviation 0.4 0.0 0.0

[0111] Table 4: Mean UVA-PF and 95% confidence intervals.

[0112]

[0113] *c: Coefficient calculated according to the above formula.

[0114] The mean UVA-PF of the sunscreen study samples was 15.6 with a coefficient of variation of 2.5%. The mean SPF / UVA-PF ratio calculated from the in vivo SPF was 1.9. The mean critical wavelength (λc) was 375 nm. The c-value was less than 17% of the mean UVA-PF value (CI[%], 17.0%), so the test was considered valid. The mean UVA-PF obtained for reference material S2 was 14.0. The obtained UVA-PF values ​​were within the expected range and the c-value was less than 17% of the mean UVA-PF value (IC[%] < 17.0%).

[0115] Example 2: In vivo evaluation of UVA-PF

[0116] Research Design and Methods

[0117] Ten female subjects aged between 20 and 61 years (mean 35 years) were recruited, all of whom had skin phototypes III to IV and participated in this study with informed consent. The inclusion criteria for the study included: healthy subjects, intact skin at the test site, consent to follow the study procedures, ability to give written consent for participation in the study, aged 18-70 years, skin phototype II to IV, and ITA° between 20° and 41°. Study exclusion criteria included: pregnancy or breastfeeding, skin disease at the application site, type 1 diabetes, gestational diabetes, diabetes with complications, insulin users, presence of diabetes-related skin disease, congenital hypoglycemic episodes, diabetic ketoacidosis and / or hyperosmolar coma, immunocompromise, use of systemic corticosteroids or immunosuppressive medications within two weeks before the start of the study, current use of antihistamines or anti-inflammatory drugs or intended use of these drugs during the study, skin disease, congenital reactions to components of the study sunscreen samples, history of allergy or sensitivity to cosmetics, hygiene products, sunscreens and / or topical products, other diseases or health risks, sun exposure to the test site within the past four weeks, participation in SPF / UVA-PF studies within the past two months, use of photosensitizing medications, history of allergy, photosensitivity or toxic reactions to sun exposure, use of self-tanning products within the past month, current artificial tanning, vaccination within 3 weeks of the study, personal or family history of skin cancer, presence of sunburn, scars and / or active skin lesions, and any other unmentioned conditions that the investigator believed could affect the study assessments.

[0118] Have the subject lie on a stretcher and mark three areas on his back, each approximately 30 cm 2 Apply the sunscreen study sample to one area, apply the control to one of the remaining areas, and leave the third area untreated. Apply and spread approximately 60 + / - 1.5 mg (corresponding to 2.0 mg / cm 2 ) sunscreen preparation. After standing for 15 to 30 minutes, the three sites were irradiated. For irradiation, a series of six long-wave ultraviolet radiation (320-400nm) doses were used, with a 25% variation between each dose.

[0119] Pigmentation of irradiated sites was assessed 2 to 24 hours after completion of each exposure. Observations were performed by trained technicians at the same relative time after completion of each UVA exposure in protected and unprotected areas. The minimum persistent pigmentation dose (MPPD) was defined as the lowest dose of long-wave UVA (320-400nm) that produced an initial response with well-defined boundaries observed 2 to 24 hours after completion of UVA exposure, on most areas exposed to UVA irradiation.

[0120] The product UVA-PF for each subject was calculated as the ratio between the MPPD of protected skin (MPPDp) and the MPPD of unprotected skin (MPPDu):

[0121]

[0122] The result was rejected if any of the following occurred in any irradiated area during the evaluation: 1) No change in pigmentation

[0123] (underexposure); 2) pigmentation changes are present in all areas (overexposure); or 3) if the progression of color changes does not follow a regular sequence.

[0124] The UVA-PF determination was repeated in a sufficient number of study subjects to obtain at least 10 valid results. The mean UVA-PF (x) and standard deviation (s) of the sunscreen study samples and controls were calculated. Next, the 95% confidence interval of the UVA-PF of the sunscreen study samples and controls was determined using the following formula:

[0125]

[0126] in:

[0127] CI95%: lower and upper limits of the 95% confidence interval;

[0128] n: number of measurements;

[0129] t: two-sided Student’s t distribution value with n-1 degrees of freedom and 95% confidence level.

[0130] result

[0131] Ten study subjects completed the study. The data values ​​obtained for each subject are shown in Table 5, and the mean UVA-PF, standard deviation, and 95% confidence interval for the sunscreen study samples and controls are shown in Table 6.

[0132] Table 5: Individual MPPD and UVA-PF results for sunscreen study samples and controls

[0133]

[0134] Table 6: Mean UVA-PF, standard deviation and 95% confidence interval for sunscreen study samples and controls.

[0135]

[0136] Example 3: In vivo evaluation of SPF

[0137] Research Design and Methods

[0138] Ten female subjects aged between 21 and 49 years (mean 37 years) were recruited, and all subjects had skin phototypes I to III and participated in this study with informed consent. The inclusion criteria of the study included: healthy subjects, intact skin at the test site, consent to follow the study procedures, ability to give written consent for participation in the study, aged 18-70 years, skin phototype I to III, and ITA° higher than 28°. Exclusion criteria included: pregnancy or breastfeeding, skin disease at the application site, type 1 diabetes, gestational diabetes, diabetes with complications, insulin users, presence of diabetes-related skin disease, congenital hypoglycemic episodes, diabetic ketoacidosis and / or hyperosmolar coma, immunocompromise, use of systemic corticosteroids or immunosuppressive medications within two weeks prior to the start of the study, current use of antihistamines or anti-inflammatory drugs or intended use of these medications during the study, skin disease, congenital reactions to components of the study sunscreen samples, history of allergy or sensitivity to cosmetics, hygiene products, sunscreens and / or topical products, other diseases or health risks, sun exposure to the test site within the past four weeks, participation in SPF / UVA-PF studies within the past two months, use of photosensitizing medications, history of allergy, photosensitivity or toxic reactions to sun exposure, use of self-tanning products within the past month, current artificial tanning, vaccinations within 3 weeks of the study, personal or family history of skin cancer, presence of sunburn, scars and / or

[0139] or active skin lesions, and any other unmentioned conditions that the investigator believed might affect the study assessments.

[0140] At the beginning of the assessment, the subject was asked to lie on a stretcher and three areas were marked on the subject's back, each approximately 30 cm 2 The first area was treated with the sunscreen study sample, the second area was treated with the control (a known sunscreen with SPF 16), and the third area was an untreated control. The sunscreen study sample and the sunscreen control were applied with a micropipette; 60 mg of material was applied for both, which corresponds to approximately 2.0 mg / cm 2 The three sites were then irradiated approximately 15 to 30 minutes after the application of the material. For irradiation, a series of six UV irradiation doses was used, with a variation of 25% (for materials with an SPF of up to 25) and 12% (for materials with an SPF higher than 25) between each dose. The series was centered on the expected value of the minimum erythema dose based on the provisional measurements previously made. The formula used to calculate the dose was:

[0141] D=1.25n× prov MEDu×SPF#

[0142] in:

[0143] D: irradiated erythema effect UV dose;

[0144] n: integers 2, 1, 0, -1, -2, -3 represent doses from 1 to 6, respectively;

[0145] prov MEDu: previously determined interim minimum erythema dose of the subject;

[0146] SPF#: Theoretical sun protection factor of the material being tested (equal to 1 for unprotected skin).

[0147] For products with SPF values ​​above 25, a factor of 1.12 is used instead of 1.25.

[0148] Erythema was assessed by trained technicians within 16 to 24 hours after irradiation. Minimal erythema dose

[0149] The MED is defined as the lowest UV dose that produces a barely perceptible, clear erythema.

[0150] The SPFi of the product for each subject was calculated as the ratio between the MED of protected skin (MEDp) and the MED of unprotected skin (MEDu):

[0151]

[0152] When evaluating any irradiated area, if no erythema developed (underexposure), if erythema developed in all subsites (overexposure), or if the progression of erythema did not follow a regular sequence, the result was rejected.

[0153] The SPF determination was repeated in a study subject population sufficient to obtain at least 10 valid results. The mean SPF (x) and standard deviation (s) of the sunscreen study samples and controls were calculated. Next, the 95% confidence interval for the SPF of the sunscreen study samples and controls was determined using the following formula:

[0154]

[0155] in:

[0156] CI95%: lower and upper limits of the 95% confidence interval;

[0157] n: number of measurements;

[0158] t: two-sided Student’s t distribution value with n-1 degrees of freedom and 95% confidence level.

[0159] result

[0160] The SPF of the sunscreen study samples measured for each of the 10 subjects is shown in Table 7, and the average SPF of the sunscreen study samples is shown in Table 8.

[0161] Table 7: Individual MED and SPF static results for sunscreen study samples and controls

[0162]

[0163]

[0164] Table 8: Mean static SPF, standard deviation and 95% confidence interval for sunscreen study samples and controls.

[0165]

[0166] Example 4: Broad spectrum UV analysis

[0167] According to the 2011 FDA standard, the UV transmittance of the blank and product plates should be obtained first and then converted to absorbance values ​​so that they can be inserted into the equation for calculating the critical wavelength. The absorption spectrum of the blank PMMA plate coated with glycerol in the range of 290nm to 400nm was measured at 1nm intervals. Approximately 0.75mg / cm 2 The amount of sunscreen sample was applied to three PMMA plates with roughened surface and spread manually with fingertips to obtain visually uniform film coating. The test plates with sunscreen research samples were placed in a drying oven for at least 15 minutes in the dark while the temperature was controlled at 28.8°C to 29.2°C.

[0168] All three PMMA plates containing the sunscreen study samples were exposed to controlled doses of UV radiation to subject the product to near-realistic conditions. The sunscreen study samples were exposed to radiation in the UVA, UVB and visible ranges, providing 800 J / cm2 equivalent to 4 MED 2 of the erythema effect energy.

[0169] After irradiating the test plates containing the sunscreen study samples, the absorbance of each of the three sample plates was measured in the range of 290 nm to 400 nm at 1 nm intervals using the test plate treated with glycerol as a reference.

[0170] The critical wavelength (λc) was determined for the sunscreen study samples applied to all test panels based on the absorption spectrum after UV irradiation. The critical wavelength is defined as the lower wavelength where the absorbance of the sunscreen study sample is equal to 90% of the total absorbance according to the following formula:

[0171]

[0172] in:

[0173] λc: critical wavelength;

[0174] A λ : Average monochromatic light absorbance of sunscreen research samples at wavelength λ.

[0175] The critical wavelength value (λc) for the sunscreen study sample is the average of the individual values ​​for each of the three test panels. To label a sunscreen product as providing broad spectrum protection, the average critical wavelength must be ≥ 370nm.

[0176] result

[0177] Figure 4 The average absorption spectrum obtained for all blank plates is shown. Figure 5 Shown are the average absorption spectra of the test panels treated with the sunscreen research samples after UV irradiation. Table 9 provides the sunscreen research sample application data and the critical wavelength (λc) for each test panel coated with the sunscreen research sample.

[0178] Table 9: Sunscreen study sample data and critical wavelength for each test panel coated with the sample.

[0179] Plate No. Sample mass (mg) λc(nm) 1 18.4 373 2 19.2 373 3 18.1 373 average 18.6 373 Standard Deviation 0.6 0.0

[0180] The critical wavelength for the sunscreen study sample was calculated to be 373 nm. Therefore, the sunscreen study sample formulation provides broad spectrum protection.

[0181] Example 5: SPF determination using the FDA guidance Labeling and Effectiveness Testing: For Over-the-Counter Human Sunscreen Drug Products.

[0182] Ten female subjects aged between 21 and 52 years (mean 38 years) were recruited, and all subjects had skin phototypes I to III and participated in this study with informed consent. The inclusion criteria of the study included: healthy subjects, intact skin at the test site, consent to follow the study procedures, ability to give written consent for participation in the study, aged 18-70 years, skin phototype I to III, and ITA° higher than 28°. Study exclusion criteria included: pregnancy or breastfeeding, skin disease at the application site, type 1 diabetes, gestational diabetes, diabetes with complications, insulin users, presence of diabetes-related skin disease, congenital hypoglycemic episodes, diabetic ketoacidosis and / or hyperosmolar coma, immunocompromise, use of systemic corticosteroids or immunosuppressive medications within two weeks before the start of the study, current use of antihistamines or anti-inflammatory drugs or intended use of these drugs during the study, skin disease, congenital reactions to components of the study sunscreen samples, history of allergy or sensitivity to cosmetics, hygiene products, sunscreens and / or topical products, other diseases or health risks, sun exposure to the test site within the past four weeks, participation in SPF / UVA-PF studies within the past two months, use of photosensitizing medications, history of allergy, photosensitivity or toxic reactions to sun exposure, use of self-tanning products within the past month, current artificial tanning, vaccination within 3 weeks of the study, personal or family history of skin cancer, presence of sunburn, scars and / or active skin lesions, and any other unmentioned conditions that the investigator believed could affect the study assessments.

[0183] At the beginning of the assessment, the subject was asked to lie on a stretcher and five areas were marked on the subject's back, each approximately 30 cm 2 First, apply approximately 60 mg (corresponding to 2.0 mg / cm 2 ) and were spread evenly by trained technicians using finger cots. After a period of at least 15 minutes, the areas where the sunscreen study samples were applied were irradiated. Areas not coated with the product were also irradiated. Application of the samples, UV radiation exposure and determination of the MED were performed under stable conditions, with the room temperature maintained between 18°C ​​and 26°C.

[0184] For products with SPF up to and including 8, a series of six doses of B+A UV radiation (290nm to 400nm) is performed with a 25% variation between each dose. For products with SPF between SPF 8 and 15, a 20% variation is used, while for products with SPF above 15, a 15% variation is used. The third output of the dose series is taken in the middle, which must be equal to the initial MEDu (previously determined) multiplied by the expected SPF value.

[0185] Erythema was assessed by trained technicians within 16 to 24 hours after irradiation. Minimal erythema dose

[0186] The MED is defined as the lowest UV dose that produces a barely perceptible, clear erythema.

[0187] The static SPFi of the sunscreen study sample for each subject was calculated as the ratio between the MED of protected skin (tpMEDp) and the MED of unprotected skin (MEDu) according to the following formula:

[0188]

[0189] SPF determinations were repeated in a sufficient number of study subjects to obtain at least 10 valid results. The mean SPF values ​​for the sunscreen study samples and controls were calculated. Next, the final SPF of the sunscreen study samples and controls was determined using the following formula:

[0190]

[0191] in:

[0192] The average value of SPFi value;

[0193] n: number of measurements;

[0194] t: two-sided Student’s t distribution value with n-1 degrees of freedom and 95% confidence level.

[0195] The labeled SPF of the sunscreen study samples is defined as the upper integer limit below the final SPF value.

[0196] result

[0197] Table 10 shows the study results for each individual subject, and Table 11 shows the averages for the sunscreen study samples and controls.

[0198] Table 10: Individual static results for MED and static SPF for products and controls.

[0199]

[0200]

[0201] Table 8: Mean static SPF, standard deviation and 95% confidence interval for sunscreen study samples and controls.

[0202]

[0203] This application also relates to the following implementation schemes:

[0204] 1. A sunscreen formulation comprising a metal oxide, squalane and one or more antioxidants.

[0205] 2. The sunscreen preparation of embodiment 1, wherein the sunscreen preparation has a higher sun protection factor (SPF) per unit mass than that of a simple metal oxide.

[0206] 3. The sunscreen formulation of embodiment 1 or 2, wherein the metal oxide is selected from zinc oxide and titanium oxide.

[0207] 4. The sunscreen formulation according to any one of the preceding embodiments, wherein the antioxidant is ethyl ferulate.

[0208] 5. The sunscreen formulation according to any one of the preceding embodiments, further comprising a solvent.

[0209] 6. The sunscreen formulation of embodiment 5, wherein the solvent is water.

[0210] 7. The sunscreen formulation according to any one of the preceding embodiments, further comprising a chelating agent.

[0211] 8. The sunscreen preparation of embodiment 6, wherein the chelating agent is selected from sodium gluconate, sodium phytate, EDTA, tetrasodium glutamate diacetate, and trisodium ethylenediamine disuccinate.

[0212] 9. The sunscreen formulation according to any one of the preceding embodiments, further comprising a surfactant.

[0213] 10. The sunscreen formulation of embodiment 8, wherein the surfactant is selected from the group consisting of decyl / octyl glucoside, cocoyl glucoside, isostearic acid, cetearyl glucoside and arachidyl glucoside.

[0214] 11. The sunscreen formulation according to any of the preceding embodiments, further comprising a humectant.

[0215] 12. The sunscreen formulation of embodiment 10, wherein the humectant is selected from glycerin, 1,2-propylene glycol, 1,3-propylene glycol, hexylene glycol, butylene glycol, sorbitol and xylitol.

[0216] 13. The sunscreen formulation according to any one of the preceding embodiments, further comprising an emulsion stabilizer.

[0217] 14. The sunscreen formulation of embodiment 13, wherein the emulsion stabilizer is selected from gum arabic, xanthan gum, cellulose gum, and microcrystalline cellulose.

[0218] 15. The sunscreen formulation according to any one of the preceding embodiments, further comprising a thickener.

[0219] 16. The sunscreen formulation of embodiment 15, wherein the thickener is selected from cetyl palmitate, cetearyl alcohol, methyl dihydroabietate, behenyl alcohol, brassic alcohol, arachidyl alcohol, coconut alcohol, sorbitan palmitate.

[0220] 17. The sunscreen formulation according to any of the preceding embodiments, further comprising an emulsifier.

[0221] 18. The sunscreen preparation according to embodiment 17, wherein the emulsifier is selected from sorbitan olivate, polyglyceryl-3 polyricinoleate, lecithin, glyceryl stearate, and cetearyl olivate.

[0222] 13. The sunscreen formulation according to any of the preceding embodiments, further comprising an emollient other than squalane.

[0223] 20. The sunscreen formulation of embodiment 19, wherein the other emollient besides squalane is selected from tricaprylin and tricaprin.

[0224] 21. The sunscreen formulation according to any of the preceding embodiments, further comprising a dispersant.

[0225] 22. The sunscreen formulation of embodiment 21, wherein the dispersant is selected from polyhydroxystearic acid.

[0226] 23. The sunscreen formulation according to any one of the preceding embodiments, further comprising a skin conditioning agent.

[0227] 24. The sunscreen formulation of embodiment 23, wherein the skin conditioning agent is selected from sodium palmitoyl proline and white water lily extract.

[0228] 25. The sunscreen formulation according to any one of the preceding embodiments, further comprising a preservative.

[0229] 26. The sunscreen formulation of embodiment 25, wherein the preservative is selected from phenoxyethanol, benzyl alcohol, hydroxyacetophenone, chlorphenesin, and potassium sorbate.

[0230] 27. The sunscreen formulation according to any of the preceding embodiments, further comprising a conditioning agent.

[0231] 28. The sunscreen formulation of embodiment 27, wherein the conditioning agent is selected from ethylhexylglycerin.

[0232] 29. The sunscreen formulation according to any one of the preceding embodiments, wherein the metal oxide is from about 5% w / w to about 25% w / w of the formulation.

[0233] 30. The sunscreen formulation according to any one of the preceding embodiments, wherein squalane is from about 1% w / w to about 25% w / w of the formulation.

[0234] 31. The sunscreen formulation according to any one of the preceding embodiments, wherein the antioxidant is from about 0.1% w / w to about 2% w / w of the formulation.

[0235] 32. The sunscreen formulation according to any one of the preceding embodiments, wherein the metal oxide is about 14% w / w of the formulation, squalane is about 5% w / w, and the antioxidant is about 0.7% w / w.

[0236] 33. A method of preventing ultraviolet damage to a subject's skin, comprising applying an effective amount of the sunscreen formulation of any one of embodiments 1 to 32 to the subject's skin.

[0237] 34. The method of embodiment 33, wherein the sunscreen formulation is applied to the skin prior to exposure to ultraviolet light.

Claims

1. A sunscreen formulation comprising zinc oxide, squalane, lecithin and one or more antioxidants, wherein the zinc oxide is from about 5% w / w to about 25% w / w of the formulation, the squalane is from about 1% w / w to about 25% w / w of the formulation, and the antioxidant is from about 0.1% w / w to about 2% w / w of the formulation.

2. The sunscreen preparation of claim 1, wherein the sunscreen preparation has a higher sun protection factor (SPF) per unit mass than zinc oxide alone.

3. A sunscreen formulation according to any one of the preceding claims, wherein the antioxidant is ethyl ferulate.

4. The sunscreen formulation according to any of the preceding claims, further comprising a solvent.

5. The sunscreen formulation of claim 4, wherein the solvent is water.

6. A sunscreen formulation according to any one of the preceding claims, further comprising a chelating agent.

7. The sunscreen formulation of claim 6, wherein the chelating agent is selected from the group consisting of sodium gluconate, sodium phytate, EDTA, tetrasodium glutamate diacetate, and trisodium ethylenediamine disuccinate.

8. The sunscreen formulation according to any one of the preceding claims, further comprising a surfactant.

9. The sunscreen formulation of claim 8, wherein the surfactant is selected from the group consisting of decyl / octyl glucoside, cocoyl glucoside, isostearic acid, cetearyl glucoside and arachidyl glucoside.

10. The sunscreen formulation of any of the preceding claims, further comprising a humectant.

11. The sunscreen formulation of claim 10, wherein the humectant is selected from the group consisting of glycerin, 1,2-propylene glycol, 1,3-propylene glycol, hexylene glycol, butylene glycol, sorbitol, and xylitol.

12. The sunscreen formulation of any of the preceding claims, further comprising an emulsion stabilizer.

13. The sunscreen formulation of claim 12, wherein the emulsion stabilizer is selected from the group consisting of gum arabic, xanthan gum, cellulose gum, and microcrystalline cellulose.

14. The sunscreen formulation according to any one of the preceding claims, further comprising a thickener.

15. The sunscreen formulation of claim 14, wherein the thickener is selected from the group consisting of cetyl palmitate, cetearyl alcohol, methyl dihydroabietate, behenyl alcohol, brassic alcohol, arachidyl alcohol, coconut alcohol, sorbitan palmitate.

16. The sunscreen formulation of any of the preceding claims, further comprising an emulsifier.

17. The sunscreen formulation of claim 16, wherein the emulsifier is selected from the group consisting of sorbitan olivate, polyglyceryl-3 polyricinoleate, glyceryl stearate, and cetearyl olivate.

18. The sunscreen formulation according to any one of the preceding claims, further comprising an emollient other than squalane.

19. The sunscreen formulation of claim 18, wherein the other emollient besides squalane is selected from the group consisting of tricaprylin and tricaprin.

20. The sunscreen formulation of any of the preceding claims, further comprising a dispersant.

21. The sunscreen formulation of claim 20, wherein the dispersant is selected from polyhydroxystearic acid.

22. The sunscreen formulation of any of the preceding claims further comprising a skin conditioning agent.

23. The sunscreen formulation of claim 22, wherein the skin conditioning agent is selected from the group consisting of sodium palmitoyl proline and white water lily extract.

24. The sunscreen formulation of any of the preceding claims, further comprising a preservative.

25. The sunscreen formulation of claim 24, wherein the preservative is selected from the group consisting of phenoxyethanol, benzyl alcohol, hydroxyacetophenone, chlorphenesin, potassium sorbate.

26. The sunscreen formulation of any of the preceding claims, further comprising a conditioning agent.

27. The sunscreen formulation of claim 26, wherein the conditioning agent is selected from ethylhexylglycerin.

28. A sunscreen formulation according to any one of the preceding claims wherein zinc oxide is about 14% w / w, squalane is about 5% w / w and the antioxidant is about 0.7% w / w of the formulation.

29. Use of a sunscreen formulation according to any one of claims 1 to 28 in the preparation of a composition for use in a method of preventing ultraviolet damage to a subject's skin, the method comprising applying to the subject's skin an effective amount of the composition.

30. The use of claim 29, wherein the sunscreen formulation is applied to the skin prior to exposure to UV rays.